Bliss GVS Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: BLISSGVS BSE: 506197

₹694.45

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #51 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Bliss GVS Pharma Limited (this stock)	7,365	64.2	10.9%	353.9%	0.22%	66	33	52

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹7,362 Cr

EV / EBITDA

38.2x

EV / Sales

9.34x

Market cap / Sales

9.35x

Earnings yield

1.56%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 230 Cr, up 32.4% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	222	51	39	₹3.6500
March 31, 2026	212	44	32	₹3.0600
Dec. 31, 2025	165	25	19	₹1.7600
Sept. 30, 2025	190	33	25	₹2.3500
June 30, 2025	163	31	21	₹2.0000
March 31, 2025	156	14	11	₹1.0800
Dec. 31, 2024	180	30	21	₹2.0000
Sept. 30, 2024	183	24	17	₹1.6300
June 30, 2024	149	26	19	₹1.8500
March 31, 2024	164	-15	-11	₹-1.1100
Dec. 31, 2023	161	29	21	₹1.9900
Sept. 30, 2023	171	46	34	₹3.2500
June 30, 2023	109	11	7	₹0.7200

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	230	221	175	216	174	165	191	191	156	172	169	182	116
Operating revenue	222	212	165	190	163	156	180	183	149	164	161	171	109
Other income	9	9	10	26	11	9	12	8	7	8	8	11	7
Operating expenses	170	167	138	172	131	142	154	157	122	139	133	129	98
Operating profit	52	44	27	18	33	14	26	25	27	25	29	42	11
Operating profit margin	23.4%	20.9%	16.3%	9.5%	20.1%	8.8%	14.3%	13.9%	18.0%	15.4%	17.8%	24.7%	10.1%
Depreciation	9	8	8	8	8	7	7	6	6	6	6	6	5
Interest	0	2	1	3	5	1	1	3	1	2	2	1	1
Exceptional items, gain / (loss)	—	0	-3	—	—	—	—	—	—	-41	—	—	—
Profit before tax	51	44	25	33	31	14	30	24	26	-15	29	46	11
Tax	13	12	7	9	10	3	9	7	7	-4	8	12	3
Net profit	—	32	19	25	21	11	21	17	19	-11	21	34	7
EPS	3.65	3.06	1.76	2.35	2.00	1.08	2.00	1.63	1.85	-1.11	1.99	3.25	0.72
Net profit (TTM)	—	97	76	78	71	69	46	46	63	51	68	77	68
EPS (TTM)	10.82	9.17	7.19	7.43	6.71	6.56	4.37	4.36	5.98	4.85	6.56	7.38	6.58

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	730	133	97
March 31, 2025	667	94	69
March 31, 2024	605	70	51
March 31, 2023	598	116	85

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	6.6%	10.2%	786^†	703^†	639^†	649^†	669^†	483^†	477^†	462^†	312^†	371^†
Operating revenue	6.8%	9.4%	730	667	605	598	636^†	466^†	442^†	427^†	298^†	349^†
Other income	—	—	56^†	36^†	34^†	51^†	33^†	18^†	35^†	36^†	14^†	22^†
Operating expenses	—	—	608^†	576^†	498^†	508^†	527^†	374^†	342^†	333^†	213^†	250^†
Operating profit	10.5%	5.9%	122^†	92^†	107^†	90^†	109^†	91^†	100^†	93^†	85^†	99^†
Operating profit margin	—	—	16.7%^†	13.7%^†	17.7%^†	15.1%^†	17.2%^†	19.6%^†	22.7%^†	21.8%^†	28.6%^†	28.3%^†
Depreciation	—	—	31^†	27^†	24^†	15^†	14^†	14^†	9^†	6^†	6^†	6^†
Interest	—	—	11^†	7^†	6^†	10^†	4^†	4^†	5^†	3^†	7^†	9^†
Exceptional items, gain / (loss)	—	—	-2^†	0^†	-41^†	0^†	3^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	4.9%	7.9%	133	94	70	116	126^†	91^†	122^†	120^†	87^†	98^†
Tax	—	—	37^†	25^†	20^†	30^†	34^†	24^†	29^†	46^†	30^†	36^†
Net profit	4.3%	7.5%	97	69	51	85	93^†	68^†	92^†	74^†	57^†	63^†
EPS	3.6%	7.0%	9.17^†	6.56^†	4.85^†	8.24^†	8.96^†	6.55^†	8.95^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	16.7%^†	13.7%^†	17.7%^†	15.1%^†	17.2%^†	19.6%^†	22.7%^†	21.8%^†	28.6%^†	28.3%^†
EBIT margin	19.8%^†	15.1%^†	12.6%^†	21.0%^†	20.5%^†	20.5%^†	28.6%^†	28.9%^†	31.4%^†	30.8%^†
PBT margin	18.3%	14.1%	11.6%	19.3%	19.9%^†	19.6%^†	27.5%^†	28.1%^†	29.1%^†	28.2%^†
Net margin	13.3%	10.3%	8.4%	14.3%	14.6%^†	14.5%^†	20.9%^†	17.4%^†	19.1%^†	17.9%^†
Interest coverage	13.01x^†	15.30x^†	13.10x^†	12.50x^†	30.23x^†	22.74x^†	27.71x^†	39.08x^†	13.49x^†	11.85x^†
Dividend payout	10.9%^†	7.6%^†	10.3%^†	6.1%^†	5.6%^†	7.6%^†	11.2%^†	—	—	—
Earnings retention	89.1%^†	92.4%^†	89.7%^†	93.9%^†	94.4%^†	92.4%^†	88.8%^†	—	—	—
Current ratio	4.90x	6.16x	—	—	—	—	—	—	—	—
Quick ratio	4.24x	5.51x	—	—	—	—	—	—	—	—
Debt to equity	0.00x	0.05x	—	—	—	—	—	—	—	—
Return on equity	8.4%	6.5%	—	—	—	—	—	—	—	—
Return on assets	7.2%	5.7%	—	—	—	—	—	—	—	—
Return on capital employed	12.3%^†	9.2%^†	—	—	—	—	—	—	—	—
Asset turnover	0.54x	0.55x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	123	-51	-75	60	64
March 31, 2025	97	-78	-27	69	29
March 31, 2024	126	-110	-21	39	87
March 31, 2023	44	-13	-26	94	-50
March 31, 2022	114	-92	-13	74	40

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	1,344	1,155	1,145	0	0	826	169	3	419	111
March 31, 2025	1,220	1,059	1,048	31	20	768	125	7	368	82
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.